Table 1.
Screening of human sera for HCoV-OC43 NP antibodies.
| Group | Total number of individuals screened | HCoV-OC43 positive (%) | HCoV-229E positive (%) | SARS-CoV positive (%) | Immunoreactivity patterns for the three structural regions of HCoV-OC43 NP |
||
|---|---|---|---|---|---|---|---|
| Type I | Type II | Type III | |||||
| 18–25 years | 26 | 24 (92.3) | 21 (80.7) | 0 | 9 | 8 | 7 |
| 50–80 yearsa | 17 | 14 (82.3) | 13 (76.4) | 0 | 7 | 3 | 4 |
| Cord blood | 15 | 14 (93.3)c | 13 (86.6) | 0 | –b | – | – |
| Total | 58 | 52 (89.7) | 47 (81.0) | 0 | 16 | 11 | 11 |
a
These specimens were taken from patients with respiratory tract infection symptoms.
b
Not determined, due to the limited quantities of cord blood collected per sample.
c
Sera from cord blood samples were analysed using purified NP as an antigen.